Article Details
Retrieved on: 2024-06-12 22:22:05
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Pfizer's failed gene therapy trial for Duchenne muscular dystrophy. Despite the lack of improvement in motor function, the study relates to biopharma advancements via genetic engineering, aimed at treating this rare disease. Tags are closely tied to the involved companies, therapies, and genetic targets.
Article found on: www.biopharmadive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here